Penumbra's First Quarter Without Guidance May Redefine How the Market Values the Acquisition

Penumbra Inc. (NYSE: PEN) reports first-quarter 2026 earnings after market close on Tuesday, May 6, 2026, with a conference call scheduled for 4:30 PM ET. The medical device maker faces a pivotal moment as investors weigh strong recent execution against the backdrop of a proposed acquisition by Boston Scientific—a deal that has shifted the narrative from operational momentum to transaction value. With the company having beaten estimates in four consecutive quarters and analysts projecting another year-over-year earnings surge, the question is whether PEN can sustain its growth trajectory through the uncertainty of a pending merger.

Part 1: Earnings Preview

Penumbra is a global healthcare company specializing in innovative medical devices for neurovascular and peripheral vascular interventions, most notably thrombectomy systems for stroke treatment and peripheral artery disease. The company's portfolio spans aspiration and thrombectomy technologies, embolization products, and access devices used by interventional specialists worldwide.

Penumbra is expected to report first-quarter 2026 results after the close on May 6, 2026. The consensus estimate calls for earnings of $1.11 per share on revenue of approximately $371 million. In the most recently reported quarter (Q4 2025), Penumbra delivered $1.18 per share, marking the fourth consecutive beat. Compared to the same quarter last year—when the company posted $0.83 per share—the current estimate implies robust 33.73% year-over-year growth, underscoring the strength of the underlying business even as the Boston Scientific acquisition looms.

Three key themes define this earnings story:

1. Thrombectomy Momentum and Market Share Gains: Penumbra's core thrombectomy franchise—particularly in the U.S.—has been the engine of growth, with Q4 2025 U.S. thrombectomy revenue up 12.4% and full-year 2025 up 19.3%. Investors will scrutinize whether this momentum carried into Q1 2026, especially as procedural volumes normalize post-pandemic and the company continues to gain share in both neuro and peripheral markets. Any commentary on adoption rates for newer devices and competitive dynamics will be critical.

2. Embolization and Access Portfolio Expansion: The embolization and access segment has been a standout performer, with Q4 2025 U.S. revenue surging 42.7% and full-year growth of 25.4%. This diversification beyond thrombectomy is key to Penumbra's long-term story, and investors will watch for signs that this high-growth trajectory is sustainable. Product mix and pricing power in this segment also directly impact gross margin trends, which improved to 67.1% for full-year 2025.

3. Boston Scientific Acquisition Overhang: The proposed acquisition by Boston Scientific has introduced uncertainty around management's willingness to provide detailed forward guidance or strategic updates. Penumbra has already suspended full-year 2026 guidance, and the company did not host a conference call for Q4 2025 results. Investors will be listening for any updates on the transaction timeline, regulatory approvals, or integration planning—though management commentary may remain limited until the deal closes.

Analyst commentary ahead of the release reflects cautious optimism. While the consensus rating sits at Hold (3.44 on a 5-point scale), the average price target of $367.93 implies modest upside from current levels. Recent downgrades from firms including RBC Capital, Canaccord Genuity, Jefferies, and Needham in January 2026 suggest some analysts are taking a wait-and-see approach given the acquisition uncertainty. However, the underlying business fundamentals—particularly the thrombectomy and embolization growth engines—remain intact, and any signs of continued execution could reinforce confidence in the company's standalone value.

Part 2: Historical Earnings Performance

Penumbra has established a consistent pattern of exceeding Wall Street expectations, delivering earnings beats in each of the past four quarters. The magnitude of these beats has varied, but the trend is unmistakable: the company has outperformed estimates by an average of 11.27% over this period.

In Q1 2025, Penumbra reported $0.83 per share against a consensus of $0.66, a substantial 25.76% beat that set the tone for the year. The following quarter saw a more modest outperformance, with Q2 2025 earnings of $0.86 versus an estimate of $0.81 (a 6.17% beat). Q3 2025 continued the trend with $0.97 reported against $0.90 expected (7.78% beat), and the most recent quarter—Q4 2025—delivered $1.18 versus $1.12 estimated, a 5.36% beat.

The pattern suggests Penumbra has been managing expectations effectively while executing on its growth initiatives. The largest beat came in Q1 2025, which may reflect conservative initial guidance or stronger-than-anticipated demand as the company ramped new products. The subsequent quarters show more moderate beats, indicating either tighter estimate calibration by analysts or a normalization of growth rates. Importantly, there have been no misses in this four-quarter window, which speaks to operational consistency and visibility into the business. Heading into Q1 2026, this track record sets a high bar—investors will expect another beat, and any miss or even an in-line result could disappoint.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Penumbra typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Penumbra's post-earnings price behavior shows significant volatility, with an average absolute Day +1 move of 8.04%—well above typical market reactions for mid-cap healthcare stocks. The Day 0 average of 1.46% is relatively muted, consistent with after-hours reporting where most of the action occurs the following session.

The most dramatic reactions came in the middle quarters of 2025: Q2 2025 saw an 11.91% Day +1 surge, Q3 2025 jumped 17.32%, and Q4 2024 (February 2025 report) rallied 12.03%—all following earnings beats that exceeded expectations. These outsized moves suggest the market has been rewarding execution and raising its assessment of the company's growth trajectory. Conversely, the July 2024 report (Q2 2024) saw a -3.47% Day +1 decline despite a beat, indicating that guidance or commentary disappointed.

The average Day +1 range of 8.46% underscores the stock's tendency to make decisive moves in either direction, with limited consolidation immediately following results. Investors should prepare for material price action: based on historical patterns, a move in the high single digits to low double digits is well within the realm of possibility, with direction hinging on whether the company beats estimates and provides constructive commentary on the business outlook.

Part 2.2: Options Market Expected Move

The options market is pricing in an expected move of 0.00% for the May 15, 2026 expiration, which appears to be a data anomaly or reflects extremely low open interest (only 126 contracts). This stands in stark contrast to Penumbra's historical average Day +1 move of 8.04%, suggesting the options market is either mispriced or the data is incomplete. Investors should expect volatility consistent with the stock's historical earnings behavior rather than relying on the current options-implied move.

Part 3: What Analysts Are Saying

Analysts maintain a cautious stance on Penumbra, with the consensus rating at Hold (3.44 on a 5-point scale) and an average price target of $367.93. This target implies approximately 13.6% upside from the current price of $323.86, suggesting analysts see moderate appreciation potential but are not aggressively bullish.

The breakdown of the 18 analyst ratings shows 4 Strong Buys, 14 Holds, and no Sell or Strong Sell ratings. This distribution reflects a divided Street: a small cohort sees significant value, while the majority takes a neutral wait-and-see posture. The absence of outright bearish calls indicates analysts aren't concerned about fundamental deterioration, but the heavy weighting toward Hold ratings suggests limited conviction in near-term upside—likely tied to the Boston Scientific acquisition uncertainty.

Sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 3.44. However, the January 2026 wave of downgrades from RBC Capital, Canaccord Genuity, Jefferies, and Needham marked a notable shift earlier in the year, as analysts moved to the sidelines following the acquisition announcement. The price target range spans from a low of $326.00 to a high of $374.00, with the current stock price sitting just below the low end of that range—suggesting some analysts believe the stock is fairly valued at current levels, while others see room for appreciation if the deal closes at favorable terms or if standalone fundamentals continue to impress.

Part 4: Technical Picture

Penumbra's technical setup heading into earnings reflects weakening momentum, with the Barchart Technical Opinion registering a Buy signal at 8%—down sharply from 40% Buy a month ago. This deterioration suggests short-term selling pressure has intensified, and the stock is losing its technical footing at a critical juncture.

Timeframe Analysis:

• Short-term (50% Sell): A moderate sell signal indicates near-term momentum has turned negative, with sellers gaining control in recent sessions.
• Medium-term (50% Buy): A moderate buy signal suggests the intermediate-term trend remains constructive, though the conflicting short-term signal points to consolidation or a potential inflection point.
• Long-term (50% Buy): A moderate buy signal reflects underlying strength in the longer-term trend, consistent with the stock's position above its 200-day moving average.

Trend Characteristics: The trend is characterized as Weak and Weakening, indicating that momentum has faded and the stock is vulnerable to further downside if earnings disappoint or fail to catalyze a reversal.

The stock is currently trading at $323.86, below its 5-day ($325.03), 10-day ($327.42), 20-day ($329.05), 50-day ($333.39), and 100-day ($332.49) moving averages—a bearish configuration that suggests the stock is in a short-term downtrend. However, it remains above the 200-day moving average at $296.15, which provides a longer-term support level and confirms the stock has not broken its broader uptrend.

Key technical levels to watch include the 200-day moving average at $296.15 as critical support and the 20-day moving average at $329.05 as near-term resistance. A strong earnings beat could propel the stock back above its short-term moving averages and reignite bullish momentum, while a miss or cautious outlook risks accelerating the recent weakness. The overall technical setup is cautionary heading into the release: with the stock below all short- and intermediate-term moving averages and the Barchart Opinion weakening, the burden is on management to deliver results that can reverse the negative technical momentum. Traders should be prepared for heightened volatility, and the stock's ability to reclaim the $330 level in the sessions following earnings will be a key tell for whether bulls can regain control.